[Canagliflozin, empagliflozin and dapagliflozin in type 2 diabetes patients]
Oubiña M, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A.
Record ID 32018001482
Original Title: Canagliflozina, empagliflozina y dapagliflozina (SGLT-2) en pacientes con diabetes tipo 2
Authors' recomendations: CONCLUSIONS High-quality evidence shows that the use of canaglifozin and empaglifozin in Type 2 diabetes patients both as monotherapy and in combination with other oral antidiabetic agents or with dietary and personal hygiene measures reduces the level of glycosylated hemoglobin just like other oral antidiabetic agents do. Also, a slight additional effect was observed related to decreased body weight. In terms of safety, a higher risk of bone fractures and lower extremity amputations was observed versus placebo. Also, a higher risk of kidney failure was observed with the use of canaglifozin only when compared with other oral antidiabetic agents or placebo. Low-quality evidence suggests that the use of these drugs would reduce mortality and the incidence of hospitalizations due to heart failure when compared with other oral antidiabetic agents. Some clinical practice guidelines recommend the use of these drugs in combination with other oral antidiabetic agents when the treatment targets have not been achieved or as monotherapy when there is contraindication for metformin, sulphonylureas, thiazolidinediones or dipeptidyl peptidase-4 enzyme inhibitor administration. Some health sponsors from high-income countries cover this technology in patients who cannot receive other oral antidiabetic agents or when the treatment target is not achieved with their use. No cost-effectiveness studies have been found in Argentina.
Project Status: Completed
Year Published: 2019
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2 Inhibitors
- Hypoglycemic Agents
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.